US Market News
2 months ago
Carlisle Companies Reports First Quarter ResultsApril 23, 2026 4:05 PM
Business Wire
Carlisle Companies Incorporated (NYSE:CSL) today announced its first quarter 2026 financial results.
Revenue of $1.1 billion, down 4% year-over-year
Diluted EPS of $3.10 and adj. EPS of $3.63, up 1% year-over-year
Operating margin of 17.1% and adj. EBITDA margin of 22.3%, up 50 bps year-over-year
Repurchased $250 million of shares, maintaining $1 billion share repurchase target for 2026
Reaffirming Full-Year 2026 outlook of +LSD revenue and ~50 bps adj. EBITDA margin expansion
Comments from Chris Koch, Chair, President and Chief Executive Officer
"Carlisle reported strong first quarter results despite challenges associated with the Middle East conflict, housing affordability, and weather. Our team executed with discipline against our Vision 2030 priorities, delivering adjusted EPS of $3.63 and increasing adjusted EBITDA margin by 50 basis points. Revenue of $1.1 billion was impacted by unfavorable winter weather conditions that constrained contractors' days on the roof throughout the quarter into early March. The quarter was shaped by three themes: our swift pricing response to oil-driven cost inflation, our disciplined execution in protecting margins, and our continued progress on innovation and other strategic priorities.
"While the cost of our raw materials does not fully correlate with oil price fluctuations, the magnitude and increasing duration of elevated oil prices has impacted our petrochemical-linked raw material inputs. We have responded quickly to this cost inflation by announcing price increases across CCM and CWT. In addition to the March price announcements, we announced a second round of price increases at CCM today to offset the additional cost pressures driven by the continued disruption in the petrochemical supply chain. With respect to freight rates, we increased freight surcharges today in addition to the surcharges put in place in March.
"At CCM, adjusted EBITDA margin expanded approximately 30 basis points year-over-year to 27.4% despite lower revenue, as COS-driven productivity gains, procurement discipline, and selling and administrative cost controls more than offset volume headwinds. At CWT, adjusted EBITDA margins decreased 40 basis points year-over-year to 15.2% due to lower volumes which was partially offset by the positive impact of operational improvements that continued to deliver measurable results, including footprint consolidation and expanded in-house polystyrene resin capacity.
"The quarter also marked meaningful progress toward our Vision 2030 goal of driving value through innovation. Our new ThermaThin 7 polyiso insulation received both the People’s Choice and Expert’s Choice awards at the 2026 International Roofing Expo. Across the business, we are on track to launch many new products in 2026, reflecting strong momentum in our innovation pipeline.
"As we move through 2026, we remain focused on integrating recent acquisitions, driving structural margin improvement through the Carlisle Operating System, and elevating the Carlisle Experience.
"Based on our progress and strategic actions to date, we are reaffirming our full-year 2026 outlook of low-single-digit revenue growth and approximately 50 basis points of adjusted EBITDA margin expansion. While increased macroeconomic uncertainty related to ongoing geopolitical conflicts could weigh on an already-soft new construction market, we are closely monitoring these dynamics and remain focused on disciplined execution and utilizing the levers in our control. Our balance sheet remains strong, and our share repurchase program continues to progress toward our $1 billion full-year target. We remain confident in the path to $40 of adjusted EPS and 25%-plus ROIC under Vision 2030."
First Quarter 2026 Financial Summary
Three Months Ended March 31,
(in millions, except per share amounts)
2026
2025
Change %
Revenues
$
1,052.1
$
1,095.8
(4
)%
Operating income
180.3
183.6
(2
)%
Operating margin
17.1
%
16.8
%
30 bps
Income from continuing operations
127.7
140.1
(9
)%
Diluted EPS
3.10
3.13
(1
)%
Adjusted EBITDA
234.6
238.4
(2
)%
Adjusted EBITDA margin
22.3
%
21.8
%
50 bps
Adjusted EPS
3.63
3.61
1
%
First Quarter 2026 Segment Highlights
Carlisle Construction Materials ("CCM")
CCM revenue decreased 5% (-6% organic) to $758 million, reflecting lower volumes due to the adverse impact of winter weather on shipment timing and continued softness in commercial new construction activity, partially offset by solid re-roofing growth.
CCM operating income decreased 6% to $184 million, and adjusted EBITDA decreased 4% to $208 million, reflecting an adjusted EBITDA margin of 27.4%, up 30 basis points year-over-year despite lower revenue. The improvement in adjusted EBITDA margin was driven by COS-led productivity gains, procurement discipline, and selling and administrative cost controls.
Carlisle Weatherproofing Technologies ("CWT")
CWT revenue decreased 1% (-3% organic) to $294 million, as M&A contributions partially offset lower volumes due to continued softness in residential and non-residential new construction markets.
CWT operating income increased 7% to $17 million, and adjusted EBITDA decreased 3% to $45 million, reflecting an adjusted EBITDA margin of 15.2%, down 40 basis points year-over-year. This margin decrease reflects the impact of lower volumes partially offset by the ongoing benefit of operational improvements, including manufacturing footprint consolidation and the expansion of in-house expanded polystyrene resin capacity.
Cash Flow
For the quarter ended March 31, 2026, cash used in operating activities was $45 million, and free cash flow used in continuing operations was $73 million, reflecting a $125 million post-year-end settlement of an accrued tax-related liability. Excluding this tax-related payment, operating cash flow improved year-over-year as less cash was deployed into working capital.
During the quarter ended March 31, 2026, we invested $28 million in capital expenditures. We also returned $296 million to shareholders through $250 million of share repurchases and $46 million of dividends.
As of March 31, 2026, we had $771 million in cash and cash equivalents and $1.0 billion available under our revolving credit facility.
Reaffirms 2026 Outlook
FY 2026 consolidated revenues up low-single-digit percentage year-over-year
CCM up low-single-digit percentage year-over-year
CWT up low-single-digit percentage year-over-year
FY 2026 adjusted EBITDA margins up ~50 basis points
Conference Call and Webcast
Carlisle will discuss first quarter 2026 results on a conference call at 5:00 p.m. ET today. The call can be accessed via webcast, along with related materials, at www.carlisle.com/investors/events-and-presentations and via telephone as follows:
Domestic toll free: 800-715-9871
International: 646-307-1963
Conference ID: 7254110
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, about our expectations, plans, objectives, future financial performance and other matters that are not historical facts. You can identify these forward-looking statements by our use of words such as "anticipate," "believe," "continues," "estimate," "expect," "forecast," "foresee," "intends," "may," "plans," "project," "pursue," "should," "will" and similar expressions. We cannot guarantee that any forward-looking statement will be realized, although we believe that we have been prudent in our plans, estimates and assumptions. Such statements are made based on known events and circumstances at the time of publication and, as such, are subject in the future to unforeseen risks and uncertainties and to assumptions that may prove to be inaccurate. It is possible that our future performance may differ materially from current expectations expressed in, or implied by, these forward-looking statements due to a variety of factors, including:
increasing price and product/service competition by foreign and domestic competitors, including new entrants;
significant reliance on our key customers;
damage to, or prolonged disruption of, our manufacturing facilities;
technological developments and changes;
the ability to continue to introduce competitive new products and services on a timely, cost-effective basis;
our mix of products/services;
increases in raw material costs that cannot be recovered in product pricing;
domestic and foreign governmental and public policy changes including environmental and industry regulations;
the ability of our customers to maintain appropriate labor levels under U.S. immigration laws, policies and practices;
the ability to meet our goals relating to our intended reduction of greenhouse gas emissions, including our net zero commitments;
threats associated with, and efforts to combat, terrorism;
protection and validity of patent and other intellectual property rights;
the identification of strategic acquisition targets and our successful completion of any transaction and integration of our strategic acquisitions;
the cyclical nature of our businesses;
the impact of information technology, cybersecurity, artificial intelligence or data security breaches at our businesses or third parties;
the outcome of pending and future litigation, including product liability claims, and governmental proceedings;
general industry and market conditions and growth rates, the condition of the financial and credit markets and general domestic and international economic conditions, including inflation, interest rate and currency exchange rate fluctuations, and tariffs;
any conflict in the international arena, including the Russian invasion of Ukraine and war in the Middle East; and
the other factors discussed in the reports we file with, or furnish to, the Securities and Exchange Commission from time to time.
Any forward-looking statement speaks only as of the date on which that statement is made, and we undertake no duty to update any forward-looking statement to reflect events or circumstances, including unanticipated events, after the date on which that statement is made, unless otherwise required by law. New factors emerge from time to time, and it is not possible for us to predict all of those factors, nor can we assess the impact of each of those factors on the business.
Non-GAAP Disclosure
Carlisle reports its financial results in accordance with the U.S. generally accepted accounting principles (GAAP). This press release also contains certain financial measures such as adjusted EPS, adjusted EBITDA, adjusted EBITDA margin, organic revenue, and free cash flow that are not recognized under GAAP. Management believes that adjusted EPS, adjusted EBITDA, adjusted EBITDA margin, and organic revenue are useful to investors because they allow for comparison to Carlisle’s and its segments' performance in prior periods without the effect of items that, by their nature, tend to obscure core operating results due to potential variability across periods based on the timing, frequency and magnitude of such items. Management believes free cash flow is useful to investors as an additional way of viewing Carlisle's liquidity and provides a more complete understanding of factors and trends affecting Carlisle's cash flows. As a result, management believes that these measures enhance the ability of investors to analyze trends in Carlisle’s businesses and evaluate Carlisle’s performance relative to similarly-situated companies. Reconciliations of these measures to amounts reported in Carlisle's consolidated financial statements are in the supplemental schedules of this press release. These non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies. Carlisle is not providing reconciliations for forward-looking non-GAAP financial measures because Carlisle does not provide GAAP financial measures on a forward-looking basis as Carlisle is unable to predict with reasonable certainty the ultimate outcome of adjusted items with unreasonable effort. These items are uncertain, depend on various factors, and could be material to Carlisle's financial results computed in accordance with GAAP.
About Carlisle Companies Incorporated
Carlisle Companies Incorporated is a leading supplier of innovative building envelope products and solutions for more energy efficient buildings. Through its building products businesses – Carlisle Construction Materials ("CCM") and Carlisle Weatherproofing Technologies ("CWT") – and family of leading brands, Carlisle delivers innovative, labor reducing and environmentally responsible products and solutions to customers through the Carlisle Experience. Carlisle is committed to generating superior shareholder returns and maintaining a balanced capital deployment approach, including investments in our businesses, strategic acquisitions, share repurchases and continued dividend increases. Leveraging its culture of continuous improvement as embodied in the Carlisle Operating System ("COS"), Carlisle has committed to achieving net-zero greenhouse gas emissions by 2050.
*EPS referenced in this release is from continuing operations unless otherwise noted.
Carlisle Companies Incorporated
Unaudited Consolidated Statements of Income
Three Months Ended
March 31,
(in millions, except per share amounts)
2026
2025
Revenues
$
1,052.1
$
1,095.8
Cost of goods sold
688.9
710.1
Selling and administrative expenses
171.8
194.0
Research and development expenses
12.1
10.7
Other operating expense (income), net
(1.0
)
(2.6
)
Operating income
180.3
183.6
Interest expense
28.3
14.8
Interest income
(8.9
)
(6.4
)
Other non-operating expense (income), net
(2.3
)
0.2
Income from continuing operations before income taxes
163.2
175.0
Provision for income taxes
35.5
34.9
Income from continuing operations
127.7
140.1
Income (loss) from discontinued operations
—
3.2
Net income
$
127.7
$
143.3
Basic earnings per share attributable to common shares:
Income from continuing operations
$
3.12
$
3.16
Income (loss) from discontinued operations
—
0.07
Basic earnings per share
$
3.12
$
3.23
Diluted earnings per share attributable to common shares:
Income from continuing operations
$
3.10
$
3.13
Income (loss) from discontinued operations
—
0.07
Diluted earnings per share
$
3.10
$
3.20
Average shares outstanding:
Basic
40.8
44.3
Diluted
41.1
44.7
Dividends declared and paid per share
$
1.10
$
1.00
Carlisle Companies Incorporated
Unaudited Condensed Consolidated Statements of Cash Flows
Three Months Ended
March 31,
(in millions)
2026
2025
Net cash provided by (used in) operating activities
$
(44.7
)
$
1.8
Investing activities:
Acquisitions, net of cash acquired
—
(49.9
)
Capital expenditures
(28.3
)
(29.0
)
Other investing activities, net
0.3
—
Net cash provided by (used in) investing activities
(28.0
)
(78.9
)
Financing activities:
Repurchases of common stock
(250.0
)
(400.0
)
Dividends paid
(45.7
)
(45.2
)
Proceeds from exercise of stock options
38.9
2.7
Withholding tax paid related to stock-based compensation
(9.9
)
(12.9
)
Other financing activities, net
(1.3
)
(1.0
)
Net cash provided by (used in) financing activities
(268.0
)
(456.4
)
Effect of foreign currency exchange rate changes on cash and cash equivalents
(0.1
)
0.2
Change in cash and cash equivalents
(340.8
)
(533.3
)
Cash and cash equivalents at beginning of period
1,112.1
753.5
Cash and cash equivalents at end of period
$
771.3
$
220.2
Carlisle Companies Incorporated
Unaudited Selected Consolidated Balance Sheet Data
(in millions)
March 31,
2026
December 31,
2025
Cash and cash equivalents
$
771.3
$
1,112.1
Long-term debt, including current portion
2,888.6
2,886.4
Total stockholders' equity
1,653.2
1,795.4
Carlisle Companies Incorporated
Unaudited Non-GAAP Financial Measures - Organic Revenue
Organic revenue (defined as revenues excluding revenue from acquisitions completed within the last 12 months and the impact of changes in foreign exchange rates versus the U.S. Dollar) is intended to provide investors and others with information about Carlisle's and its segments' recurring operating performance. This information differs from revenue determined in accordance with accounting principles generally accepted in the United States of America ("GAAP") and should not be considered in isolation or as a substitute for measures of performance determined in accordance with GAAP. Carlisle's and its segments' organic revenue follows, which may not be comparable to similarly titled measures reported by other companies.
Three Months Ended March 31,
(in millions, except percentages)
CSL
CCM
CWT
2025 Revenues (GAAP)
$
1,095.8
$
798.5
$
297.3
Organic
(55.0
)
(5.0
)%
(46.2
)
(5.8
)%
(8.8
)
(3.0
)%
Acquisitions
4.2
0.4
%
—
—
%
4.2
1.4
%
FX impact
7.1
0.6
%
5.8
0.7
%
1.3
0.5
%
Total change
(43.7
)
(4.0
)%
(40.4
)
(5.1
)%
(3.3
)
(1.1
)%
2026 Revenues (GAAP)
$
1,052.1
$
758.1
$
294.0
Carlisle Companies Incorporated
Unaudited Non-GAAP Financial Measures - Free Cash Flow
Free cash flow (defined as net cash provided by operating activities less capital expenditures) is intended to provide investors and others with information about Carlisle's liquidity and provides a more complete understanding of factors and trends affecting Carlisle's cash flows. This information differs from operating cash flow determined in accordance with GAAP and should not be considered in isolation or as a substitute for measures of performance determined in accordance with GAAP. Carlisle's free cash flow follows, which may not be comparable to similarly titled measures reported by other companies.
Three Months Ended
March 31,
(in millions)
2026
2025
Net cash provided by (used in) operating activities (GAAP)
$
(44.7
)
$
1.8
Less: Operating cash flow from discontinued operations
—
3.2
Operating cash flow from (used in) continuing operations
$
(44.7
)
$
(1.4
)
Capital expenditures (GAAP)
$
(28.3
)
$
(29.0
)
Less: Capital expenditures at discontinued operations
—
—
Capital expenditures at continuing operations
$
(28.3
)
$
(29.0
)
Operating cash flow from (used in) continuing operations
$
(44.7
)
$
(1.4
)
Capital expenditures at continuing operations
(28.3
)
(29.0
)
Free cash flow from (used in) continuing operations
$
(73.0
)
$
(30.4
)
Carlisle Companies Incorporated
Unaudited Non-GAAP Financial Measures - EBIT, Adjusted EBIT, Adjusted EBITDA and Adjusted EBITDA Margin
Earnings before interest and taxes ("EBIT") (defined as net income excluding income/loss from discontinued operations, interest expense, interest income, and provision for income taxes), adjusted EBIT (defined as EBIT excluding gains/losses and costs from acquisitions, dispositions, restructuring, impairment, casualty losses and insurance recoveries, legal settlements, pension settlements, and debt extinguishment), adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA") (defined as adjusted EBIT excluding depreciation and amortization) and adjusted EBITDA margin (defined as adjusted EBITDA divided by total revenues) are intended to provide investors and others with information about Carlisle's and its segments' performance without the effect of items that, by their nature, tend to obscure core operating results due to potential variability across periods based on the timing, frequency and magnitude of such items. As a result, management believes that these measures enhance the ability of investors to analyze trends in Carlisle's businesses and evaluate Carlisle's performance relative to similarly-situated companies. This information differs from net income and operating income determined in accordance with GAAP and should not be considered in isolation or as a substitute for measures of performance determined in accordance with GAAP. Carlisle's and its segments' EBIT, adjusted EBIT, adjusted EBITDA and adjusted EBITDA margin follows, which may not be comparable to similarly titled measures reported by other companies.
Three Months Ended
March 31,
(in millions, except percentages)
2026
2025
Net income (GAAP)
$
127.7
$
143.3
Less: Income from discontinued operations (GAAP)
—
3.2
Income from continuing operations (GAAP)
127.7
140.1
Provision for income taxes
35.5
34.9
Interest expense
28.3
14.8
Interest income
(8.9
)
(6.4
)
EBIT
182.6
183.4
Non-comparable (gains) / losses and costs related to:
Acquisitions
0.4
6.8
Dispositions
0.1
0.1
Restructuring
2.4
0.1
Legal settlements
(0.1
)
0.2
Total non-comparable items
2.8
7.2
Adjusted EBIT
185.4
190.6
Depreciation
18.8
17.7
Amortization
30.4
30.1
Adjusted EBITDA
$
234.6
$
238.4
Divided by:
Total revenues
$
1,052.1
$
1,095.8
Adjusted EBITDA margin
22.3
%
21.8
%
Carlisle Companies Incorporated
Unaudited Non-GAAP Financial Measures - EBIT, Adjusted EBIT, Adjusted EBITDA and Adjusted EBITDA Margin
Three Months Ended March 31, 2026
Three Months Ended March 31, 2025
(in millions, except percentages)
CCM
CWT
Corporate
CCM
CWT
Corporate
Operating income (loss) (GAAP)
$
184.0
$
17.3
$
(21.0
)
$
194.8
$
16.2
$
(27.4
)
Non-operating expense (income), net
0.1
(0.1
)
(2.3
)
(0.1
)
—
0.3
EBIT
183.9
17.4
(18.7
)
194.9
16.2
(27.7
)
Non-comparable (gains) / losses and costs related to:
Acquisitions
—
0.2
0.2
—
4.4
2.4
Dispositions
—
0.1
—
—
0.1
—
Restructuring
1.1
1.3
—
—
0.1
—
Legal settlements
0.1
(0.2
)
—
—
0.2
—
Total non-comparable items
1.2
1.4
0.2
—
4.8
2.4
Adjusted EBIT
185.1
18.8
(18.5
)
194.9
21.0
(25.3
)
Depreciation
13.4
5.1
0.3
12.6
4.7
0.4
Amortization
9.4
20.9
0.1
9.0
20.6
0.5
Adjusted EBITDA
$
207.9
$
44.8
$
(18.1
)
$
216.5
$
46.3
$
(24.4
)
Divided by:
Total revenues
$
758.1
$
294.0
$
—
$
798.5
$
297.3
$
—
Adjusted EBITDA margin
27.4
%
15.2
%
NM
27.1
%
15.6
%
NM
Carlisle Companies Incorporated
Unaudited Non-GAAP Financial Measures - Adjusted Net Income and Adjusted EPS
Three Months Ended
March 31, 2026
Three Months Ended
March 31, 2025
(in millions, except per share amounts)
Pre-tax
Impact
After-tax
Impact(1)
Impact to
Diluted
EPS(2)
Pre-tax
Impact
After-tax
Impact(1)
Impact to
Diluted
EPS(2)
Net income (GAAP)
$
127.7
$
3.10
$
143.3
$
3.20
Less: Income from discontinued operations (GAAP)
—
—
3.2
0.07
Income from continuing operations (GAAP)
127.7
3.10
140.1
3.13
Non-comparable (gains) / losses and costs related to:
Acquisitions
0.4
0.3
0.01
6.8
5.2
0.12
Dispositions
0.1
0.1
—
0.1
0.1
—
Restructuring
2.4
1.9
0.04
0.1
0.1
—
Legal settlements
(0.1
)
—
—
0.2
0.2
0.01
Acquisition-related amortization(3)
28.8
22.1
0.54
28.4
21.6
0.48
Discrete tax items(4)
—
(2.4
)
(0.06
)
—
(5.8
)
(0.13
)
Total adjustments
22.0
0.53
21.4
0.48
Adjusted net income
$
149.7
$
3.63
$
161.5
$
3.61
(1)
The impact to net income reflects the tax effect of noted items, which is calculated at a blended tax rate based on Carlisle's operations and the jurisdictions in which we operate.
(2)
The per share impact of adjustments to each period is based on diluted shares outstanding using the two-class method.
(3)
Acquisition-related amortization includes the amortization of customer relationships, technology, trade names and other intangible assets recorded in purchase accounting in connection with a business combination. These intangible assets contribute to revenue generation and the amortization of these assets will recur until such intangible assets are fully amortized.
(4)
Discrete tax items include current period tax expense or benefit related to prior year items, the tax impact of foreign currency gains and losses, or changes in tax laws or rates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260423455856/en/
Mehul Patel
Vice President, Investor Relations
(310) 592-9668
mpatel@carlisle.com
Original: Carlisle Companies Reports First Quarter Results
US Market News
5 months ago
Carlisle Companies Reports Fourth Quarter ResultsFebruary 3, 2026 4:05 PM
Business Wire
Carlisle Companies Incorporated (NYSE:CSL) today announced its fourth quarter 2025 financial results.
Fourth quarter revenue of $1.1 billion, up 0.4% year-over-year
Fourth quarter diluted EPS of $3.19 and adj. EPS of $3.90
Generated $1.1 billion in operating cash flow in 2025
Repurchased $300 million of shares in Q4, totaling $1.3 billion of share repurchases in 2025
2026 outlook includes LSD revenue growth and ~50 bps of adj. EBITDA margin expansion
Comments from Chris Koch, Chair, President and Chief Executive Officer
"Throughout 2025, despite continued headwinds in new construction and a complex economic environment, we continued to execute against our Vision 2030 strategy, and we remain very confident in our key long-term financial objective of delivering $40 of adjusted EPS. Over the course of the year, we made progress on all our key pillars of Vision 2030. We increased investments in innovation to develop new market-leading products. We enhanced our emphasis on the Carlisle Operating System ("COS") and expanded automation in our factories to drive operational excellence. We added significant management talent and further elevated the Carlisle Experience to strengthen customer loyalty and service. And above all else, we continued to deliver on our commitment to being superior capital allocators.
"Carlisle’s performance during 2025 adds to our history of resilience through the economic cycles and challenges we have faced over the years, such as the Covid pandemic. We delivered another solid year of cash flow, generating over $1 billion of operating cash flow, which continued to provide balance sheet optionality. As the M&A environment in 2025 was challenging, we turned a significant portion of that cash flow to share repurchases, as we continued to see this as a solid opportunity for capital deployment.
"In the fourth quarter, revenue increased 0.4% to $1.1 billion. At CCM, solid re-roofing demand, which represents approximately 70% of our commercial roofing business, continued to help stabilize our business as new construction markets work through the bottom of the cycle. At CWT, our recent acquisitions and operational initiatives contributed to revenue growth, and we are well-positioned to capitalize on the growing need for energy-efficient weatherproofing solutions.
"North America is the most attractive building-products market globally, supported by strong, long-term fundamentals including the demand for energy-efficient solutions, the need to improve labor productivity, and the recurring maintenance requirements of an aging non-residential building stock—over 70% of which is more than 25 years old. Buildings are a critical and indispensable component of the physical economy. They must be built, maintained, and continuously improved. This structural reality reinforces the durability and necessity of our end markets.
"Carlisle’s imperative business continues to benefit from a strong re-roofing market, and we continued to benefit from our position as a North American leader in the world’s largest building-products market. Carlisle’s leadership position in this essential market, highly responsive cost structure combined with the discipline of COS and our proven capital allocation framework, continues to translate into superior and sustainable margin performance.
"Looking to 2026, our outlook reflects low-single-digit revenue growth with approximately 50 basis points of adjusted EBITDA margin expansion. While we expect the current challenging market conditions to continue into the first half of the year, our solid financial position, robust cash flow, and ongoing commitment to operational excellence enable us to continue generating strong returns, pursue value-enhancing acquisitions, and deliver shareholder value. We also plan to repurchase up to $1 billion of shares in 2026."
Fourth Quarter and Full Year 2025 Financial Summary
Three Months Ended
December 31,
Year Ended
December 31,
(in millions, except per share amounts)
2025
2024
Change %
2025
2024
Change %
Revenues
$
1,127.7
$
1,122.9
0.4
%
$
5,019.9
$
5,003.6
0.3
%
Operating income
190.0
224.0
(15
)%
1,002.5
1,143.1
(12
)%
Operating margin
16.8
%
19.9
%
-310 bps
20.0
%
22.8
%
-280 bps
Income from continuing operations
133.4
162.4
(18
)%
742.5
865.1
(14
)%
Diluted EPS
3.19
3.56
(10
)%
17.16
18.34
(6
)%
Adjusted EBITDA
249.0
281.7
(12
)%
1,225.4
1,332.7
(8
)%
Adjusted EBITDA margin
22.1
%
25.1
%
-300 bps
24.4
%
26.6
%
-220 bps
Adjusted EPS
3.90
4.47
(13
)%
19.40
20.20
(4
)%
Fourth Quarter 2025 Segment Highlights
Carlisle Construction Materials ("CCM")
CCM revenue decreased 0.8% (-1% organic) to $827 million, as healthy re-roof activity was more than offset by continued softness in commercial new construction activity.
CCM operating income decreased 11% to $198 million, and adjusted EBITDA decreased 10% to $222 million, reflecting an adjusted EBITDA margin of 26.8%. The decrease in adjusted EBITDA was primarily due to strategic investments in the business to support longer-term growth initiatives.
Carlisle Weatherproofing Technologies ("CWT")
CWT revenue increased 4% (-7% organic) to $301 million, as M&A contributions more than offset continued softness in residential and non-residential new construction markets.
CWT operating income decreased 46% to $14 million, and adjusted EBITDA decreased 10% to $48 million, reflecting an adjusted EBITDA margin of 15.9%. The decrease in adjusted EBITDA was primarily due to a decline in volumes.
Cash Flow
For the year ended December 31, 2025, cash provided by operating activities was $1.1 billion, and free cash flow from continuing operations was $972 million.
During the year ended December 31, 2025, we invested $241 million in the business with $131 million in capital expenditures and $110 million in acquisitions. We also returned $1.5 billion to shareholders through $1.3 billion of share repurchases and $181 million of dividends.
As of December 31, 2025, we had $1.1 billion in cash and cash equivalents and $1.0 billion available under our revolving credit facility.
2026 Outlook
FY 2026 consolidated revenues up low-single-digit percentage year-over-year
CCM up low-single-digit percentage year-over-year
CWT up low-single-digit percentage year-over-year
FY 2026 adjusted EBITDA margins up ~50 basis points
Conference Call and Webcast
Carlisle will discuss fourth quarter 2025 results on a conference call at 5:00 p.m. ET today. The call can be accessed via webcast, along with related materials, at www.carlisle.com/investors/events-and-presentations and via telephone as follows:
Domestic toll free: 800-549-8228
International: 646-564-2877
Conference ID: 98812
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally use words such as "expect," "foresee," "anticipate," "believe," "project," "should," "estimate," "will," "plans," "intends," "forecast," and similar expressions, and reflect our expectations concerning the future. Such statements are made based on known events and circumstances at the time of publication and, as such, are subject in the future to unforeseen risks and uncertainties. It is possible that our future performance may differ materially from current expectations expressed in these forward-looking statements, due to a variety of factors such as: increasing price and product/service competition by foreign and domestic competitors, including new entrants; technological developments and changes; the ability to continue to introduce competitive new products and services on a timely, cost-effective basis; our mix of products/services; increases in raw material costs that cannot be recovered in product pricing; domestic and foreign governmental and public policy changes including environmental and industry regulations; the ability of our customers to maintain appropriate labor levels under U.S. immigration laws, policies and practices; the ability to meet our goals relating to our intended reduction of greenhouse gas emissions, including our net zero commitments; threats associated with and efforts to combat terrorism; protection and validity of patent and other intellectual property rights; the identification of strategic acquisition targets and our successful completion of any transaction and integration of our strategic acquisitions; our successful completion of strategic dispositions; the cyclical nature of our businesses; the impact of information technology, cybersecurity, artificial intelligence or data security breaches at our businesses or third parties; the outcome of pending and future litigation and governmental proceedings; and the other factors discussed in the reports we file with or furnish to the Securities and Exchange Commission from time to time. In addition, such statements could be affected by general industry and market conditions and growth rates, the condition of the financial and credit markets and general domestic and international economic conditions, including inflation, interest rate and currency exchange rate fluctuations, and tariffs. Further, any conflict in the international arena, including the Russian invasion of Ukraine and war in the Middle East, may adversely affect general market conditions and our future performance. Any forward-looking statement speaks only as of the date on which that statement is made, and we undertake no duty to update any forward-looking statement to reflect events or circumstances, including unanticipated events, after the date on which that statement is made, unless otherwise required by law. New factors emerge from time to time and it is not possible for management to predict all of those factors, nor can it assess the impact of each of those factors on the business.
Non-GAAP Disclosure
Carlisle reports its financial results in accordance with the U.S. generally accepted accounting principles (GAAP). This press release also contains certain financial measures such as adjusted EPS, adjusted EBITDA, adjusted EBITDA margin, organic revenue, and free cash flow that are not recognized under GAAP. Management believes that adjusted EPS, adjusted EBITDA, adjusted EBITDA margin, and organic revenue are useful to investors because they allow for comparison to Carlisle’s and its segments' performance in prior periods without the effect of items that, by their nature, tend to obscure core operating results due to potential variability across periods based on the timing, frequency and magnitude of such items. Management believes free cash flow is useful to investors as an additional way of viewing Carlisle's liquidity and provides a more complete understanding of factors and trends affecting Carlisle's cash flows. As a result, management believes that these measures enhance the ability of investors to analyze trends in Carlisle’s businesses and evaluate Carlisle’s performance relative to similarly-situated companies. Reconciliations of these measures to amounts reported in Carlisle's consolidated financial statements are in the supplemental schedules of this press release. These non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies. Carlisle is not providing reconciliations for forward-looking non-GAAP financial measures because Carlisle does not provide GAAP financial measures on a forward-looking basis as Carlisle is unable to predict with reasonable certainty the ultimate outcome of adjusted items with unreasonable effort. These items are uncertain, depend on various factors, and could be material to Carlisle's financial results computed in accordance with GAAP.
About Carlisle Companies Incorporated
Carlisle Companies Incorporated is a leading supplier of innovative building envelope products and solutions for more energy efficient buildings. Through its building products businesses – Carlisle Construction Materials ("CCM") and Carlisle Weatherproofing Technologies ("CWT") – and family of leading brands, Carlisle delivers innovative, labor reducing and environmentally responsible products and solutions to customers through the Carlisle Experience. Carlisle is committed to generating superior shareholder returns and maintaining a balanced capital deployment approach, including investments in our businesses, strategic acquisitions, share repurchases and continued dividend increases. Leveraging its culture of continuous improvement as embodied in the Carlisle Operating System ("COS"), Carlisle has committed to achieving net-zero greenhouse gas emissions by 2050.
*EPS referenced in this release is from continuing operations unless otherwise noted.
Carlisle Companies Incorporated
Unaudited Consolidated Statements of Income
Three Months Ended
December 31,
Year Ended
December 31,
(in millions, except per share amounts)
2025
2024
2025
2024
Revenues
$
1,127.7
$
1,122.9
$
5,019.9
$
5,003.6
Cost of goods sold
747.1
717.4
3,227.3
3,115.9
Selling and administrative expenses
176.6
174.9
745.4
722.8
Research and development expenses
12.9
8.8
47.1
35.4
Other operating expense (income), net
1.1
(2.2
)
(2.4
)
(13.6
)
Operating income
190.0
224.0
1,002.5
1,143.1
Interest expense
27.7
17.3
78.5
73.3
Interest income
(11.3
)
(16.0
)
(25.9
)
(60.3
)
Other non-operating expense (income), net
1.2
20.7
1.1
19.2
Income from continuing operations before income taxes
172.4
202.0
948.8
1,110.9
Provision for income taxes
39.0
39.6
206.3
245.8
Income from continuing operations
133.4
162.4
742.5
865.1
Income (loss) from discontinued operations
(6.0
)
0.4
(1.8
)
446.7
Net income
$
127.4
$
162.8
$
740.7
$
1,311.8
Basic earnings per share attributable to common shares:
Income from continuing operations
$
3.21
$
3.60
$
17.31
$
18.58
Income (loss) from discontinued operations
(0.14
)
0.01
(0.04
)
9.59
Basic earnings per share
$
3.07
$
3.61
$
17.27
$
28.17
Diluted earnings per share attributable to common shares:
Income from continuing operations
$
3.19
$
3.56
$
17.16
$
18.34
Income (loss) from discontinued operations
(0.14
)
0.01
(0.04
)
9.48
Diluted earnings per share
$
3.05
$
3.57
$
17.12
$
27.82
Average shares outstanding:
Basic
41.5
45.0
42.8
46.5
Diluted
41.8
45.5
43.2
47.1
Dividends declared and paid per share
$
1.10
$
1.00
$
4.20
$
3.70
Carlisle Companies Incorporated
Unaudited Condensed Consolidated Statements of Cash Flows
Year Ended
December 31,
(in millions)
2025
2024
Net cash provided by operating activities
$
1,101.8
$
1,030.3
Investing activities:
Proceeds from sale of discontinued operations, net of cash disposed
—
1,998.0
Capital expenditures
(131.2
)
(113.3
)
Acquisitions, net of cash acquired
(109.6
)
(676.9
)
Other investing activities
0.4
21.8
Net cash provided by (used in) investing activities
(240.4
)
1,229.6
Financing activities:
Proceeds from notes
987.8
—
Repayments of notes
—
(400.0
)
Borrowings from revolving credit facility
—
22.0
Repayments of revolving credit facility
—
(22.0
)
Repurchases of common stock
(1,300.0
)
(1,585.9
)
Dividends paid
(181.1
)
(172.4
)
Proceeds from exercise of stock options
23.5
80.2
Withholding tax paid related to stock-based compensation
(13.5
)
(18.1
)
Other financing activities
(20.4
)
(14.0
)
Net cash provided by (used in) financing activities
(503.7
)
(2,110.2
)
Effect of foreign currency exchange rate changes on cash and cash equivalents
0.9
(1.7
)
Change in cash and cash equivalents
358.6
148.0
Less: change in cash and cash equivalents of discontinued operations
—
(28.8
)
Cash and cash equivalents at beginning of period
753.5
576.7
Cash and cash equivalents at end of period
$
1,112.1
$
753.5
Carlisle Companies Incorporated
Unaudited Selected Consolidated Balance Sheet Data
(in millions)
December 31, 2025
December 31, 2024
Cash and cash equivalents
$
1,112.1
$
753.5
Long-term debt, including current portion
2,886.4
1,890.6
Total stockholders' equity
1,795.4
2,463.3
Carlisle Companies Incorporated
Unaudited Non-GAAP Financial Measures - Organic Revenue
Organic revenue (defined as revenues excluding revenue from acquisitions completed within the last 12 months and the impact of changes in foreign exchange rates versus the U.S. Dollar) is intended to provide investors and others with information about Carlisle's and its segments' recurring operating performance. This information differs from revenue determined in accordance with accounting principles generally accepted in the United States of America ("GAAP") and should not be considered in isolation or as a substitute for measures of performance determined in accordance with GAAP. Carlisle's and its segments' organic revenue follows, which may not be comparable to similarly titled measures reported by other companies.
Three Months Ended December 31,
(in millions, except percentages)
CSL
CCM
CWT
2024 Revenues (GAAP)
$
1,122.9
$
833.6
$
289.3
Organic
(28.2
)
(2.5
)%
(9.0
)
(1.1
)%
(19.2
)
(6.6
)%
Acquisitions
30.4
2.7
%
—
—
%
30.4
10.5
%
FX impact
2.6
0.2
%
2.2
0.3
%
0.4
0.1
%
Total change
4.8
0.4
%
(6.8
)
(0.8
)%
11.6
4.0
%
2025 Revenues (GAAP)
$
1,127.7
$
826.8
$
300.9
Year Ended December 31,
(in millions, except percentages)
CSL
CCM
CWT
2024 Revenues (GAAP)
$
5,003.6
$
3,704.3
$
1,299.3
Organic
(146.5
)
(2.9
)%
(26.8
)
(0.7
)%
(119.7
)
(9.2
)%
Acquisitions
158.3
3.2
%
38.8
1.0
%
119.5
9.2
%
FX impact
4.5
—
%
5.4
0.2
%
(0.9
)
(0.1
)%
Total change
16.3
0.3
%
17.4
0.5
%
(1.1
)
(0.1
)%
2025 Revenues (GAAP)
$
5,019.9
$
3,721.7
$
1,298.2
Carlisle Companies Incorporated
Unaudited Non-GAAP Financial Measures - Free Cash Flow
Free cash flow (defined as net cash provided by operating activities less capital expenditures) is intended to provide investors and others with information about Carlisle's liquidity and provides a more complete understanding of factors and trends affecting Carlisle's cash flows. This information differs from operating cash flow determined in accordance with GAAP and should not be considered in isolation or as a substitute for measures of performance determined in accordance with GAAP. Carlisle's free cash flow follows, which may not be comparable to similarly titled measures reported by other companies.
Three Months Ended
December 31,
Year Ended
December 31,
(in millions)
2025
2024
2025
2024
Operating cash flow (GAAP)
$
386.0
$
370.6
$
1,101.8
$
1,030.3
Less: operating cash flow from discontinued operations
(6.0
)
(7.1
)
(1.8
)
(8.9
)
Operating cash flow from continuing operations
$
392.0
$
377.7
$
1,103.6
$
1,039.2
Capital expenditures (GAAP)
$
(39.9
)
$
(36.6
)
$
(131.2
)
$
(113.3
)
Less: capital expenditures at discontinued operations
—
—
—
(12.4
)
Capital expenditures at continuing operations
$
(39.9
)
$
(36.6
)
$
(131.2
)
$
(100.9
)
Operating cash flow from continuing operations
$
392.0
$
377.7
$
1,103.6
$
1,039.2
Capital expenditures at continuing operations
(39.9
)
(36.6
)
(131.2
)
(100.9
)
Free cash flow from continuing operations
$
352.1
$
341.1
$
972.4
$
938.3
Carlisle Companies Incorporated
Unaudited Non-GAAP Financial Measures - EBIT, Adjusted EBIT, Adjusted EBITDA and Adjusted EBITDA Margin
Earnings before interest and taxes ("EBIT") (defined as net income excluding income/loss from discontinued operations, interest expense, interest income, and provision for income taxes), adjusted EBIT (defined as EBIT excluding gains/losses and costs from acquisitions, dispositions, restructuring, impairment, casualty losses and insurance recoveries, legal settlements, pension settlements, and debt extinguishment), adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA") (defined as adjusted EBIT excluding depreciation and amortization) and adjusted EBITDA margin (defined as adjusted EBITDA divided by total revenues) are intended to provide investors and others with information about Carlisle's and its segments' performance without the effect of items that, by their nature, tend to obscure core operating results due to potential variability across periods based on the timing, frequency and magnitude of such items. As a result, management believes that these measures enhance the ability of investors to analyze trends in Carlisle's businesses and evaluate Carlisle's performance relative to similarly-situated companies. This information differs from net income and operating income determined in accordance with GAAP and should not be considered in isolation or as a substitute for measures of performance determined in accordance with GAAP. Carlisle's and its segments' EBIT, adjusted EBIT, adjusted EBITDA and adjusted EBITDA margin follows, which may not be comparable to similarly titled measures reported by other companies.
Three Months Ended
December 31,
Year Ended
December 31,
(in millions, except percentages)
2025
2024
2025
2024
Net income (GAAP)
$
127.4
$
162.8
$
740.7
$
1,311.8
Less: Income (loss) from discontinued operations
(6.0
)
0.4
(1.8
)
446.7
Income from continuing operations (GAAP)
133.4
162.4
742.5
865.1
Provision for income taxes
39.0
39.6
206.3
245.8
Interest expense
27.7
17.3
78.5
73.3
Interest income
(11.3
)
(16.0
)
(25.9
)
(60.3
)
EBIT
188.8
203.3
1,001.4
1,123.9
Plus (gains) / losses and costs from:
Acquisitions
1.6
10.2
11.5
15.0
Dispositions
(0.3
)
0.2
(0.4
)
(0.4
)
Restructuring
5.4
0.2
9.8
2.9
Casualty losses and insurance recoveries
—
—
—
(5.0
)
Legal settlements
2.0
0.7
3.6
2.6
Pension settlements
1.5
21.1
3.0
21.1
Total non-comparable items
10.2
32.4
27.5
36.2
Adjusted EBIT
199.0
235.7
1,028.9
1,160.1
Depreciation
19.3
18.5
74.6
70.2
Amortization
30.7
27.5
121.9
102.4
Adjusted EBITDA
$
249.0
$
281.7
$
1,225.4
$
1,332.7
Divided by:
Total revenues
$
1,127.7
$
1,122.9
$
5,019.9
$
5,003.6
Adjusted EBITDA margin
22.1
%
25.1
%
24.4
%
26.6
%
Carlisle Companies Incorporated
Unaudited Non-GAAP Financial Measures - EBIT, Adjusted EBIT, Adjusted EBITDA and Adjusted EBITDA Margin
Three Months Ended
December 31, 2025
Three Months Ended
December 31, 2024
(in millions)
CCM
CWT
Corporate and unallocated
CCM
CWT
Corporate and unallocated
Operating income (loss) (GAAP)
$
198.3
$
13.6
$
(21.9
)
$
223.3
$
25.4
$
(24.7
)
Non-operating expense (income), net
0.2
—
1.0
0.8
(1.3
)
21.2
EBIT
198.1
13.6
(22.9
)
222.5
26.7
(45.9
)
Plus (gains) / losses and costs from:
Acquisitions
—
1.2
0.4
—
2.7
7.5
Dispositions
(0.2
)
(0.1
)
—
0.2
—
—
Restructuring
0.3
5.1
—
0.1
0.1
—
Legal settlements
0.5
1.5
—
—
0.7
—
Pension settlements
—
—
1.5
—
—
21.1
Total non-comparable items
0.6
7.7
1.9
0.3
3.5
28.6
Adjusted EBIT
198.7
21.3
(21.0
)
222.8
30.2
(17.3
)
Depreciation
13.5
5.4
0.4
13.4
4.7
0.4
Amortization
9.4
21.0
0.3
9.0
18.0
0.5
Adjusted EBITDA
$
221.6
$
47.7
$
(20.3
)
$
245.2
$
52.9
$
(16.4
)
Divided by:
Total revenues
$
826.8
$
300.9
$
—
$
833.6
$
289.3
$
—
Adjusted EBITDA margin
26.8
%
15.9
%
NM
29.4
%
18.3
%
NM
Year Ended
December 31, 2025
Year Ended
December 31, 2024
(in millions, except percentages)
CCM
CWT
Corporate and unallocated
CCM
CWT
Corporate and unallocated
Operating income (loss) (GAAP)
$
997.2
$
101.9
$
(96.6
)
$
1,084.3
$
173.6
$
(114.8
)
Non-operating expense (income), net
0.2
0.3
0.6
0.8
(1.3
)
19.7
EBIT
997.0
101.6
(97.2
)
1,083.5
174.9
(134.5
)
Plus (gains) / losses and costs from:
Acquisitions
—
7.2
4.3
1.9
2.7
10.4
Dispositions
(0.2
)
(0.3
)
0.1
—
(0.4
)
—
Restructuring
0.4
9.4
—
1.7
1.2
—
Casualty losses and insurance recoveries
—
—
—
(5.0
)
—
—
Legal settlements
0.5
3.1
—
1.0
1.6
—
Pension settlement
—
—
3.0
—
—
21.1
Total non-comparable items
0.7
19.4
7.4
(0.4
)
5.1
31.5
Adjusted EBIT
997.7
121.0
(89.8
)
1,083.1
180.0
(103.0
)
Depreciation
52.5
20.5
1.6
51.5
17.1
1.6
Amortization
36.8
83.3
1.8
29.2
71.2
2.0
Adjusted EBITDA
$
1,087.0
$
224.8
$
(86.4
)
$
1,163.8
$
268.3
$
(99.4
)
Divided by:
Total revenues
$
3,721.7
$
1,298.2
$
—
$
3,704.3
$
1,299.3
$
—
Adjusted EBITDA margin
29.2
%
17.3
%
NM
31.4
%
20.6
%
NM
Carlisle Companies Incorporated
Unaudited Non-GAAP Financial Measures - Adjusted Net Income and Adjusted EPS
Three Months Ended
December 31, 2025
Three Months Ended
December 31, 2024
(in millions, except per share amounts)
Pre-tax
Impact
After-tax
Impact(1)
Impact to Diluted EPS(2)
Pre-tax
Impact
After-tax
Impact(1)
Impact to Diluted EPS(2)
Net income (GAAP)
$
127.4
$
3.05
$
162.8
$
3.57
Less: Income from discontinued operations (GAAP)
(6.0
)
(0.14
)
0.4
0.01
Income from continuing operations (GAAP)
133.4
3.19
162.4
3.56
Plus (gains) / losses and costs from:
Acquisitions
1.6
1.2
0.03
10.2
7.8
0.17
Dispositions
(0.3
)
(0.2
)
—
0.2
0.1
—
Restructuring
5.4
4.2
0.10
0.2
0.2
—
Legal settlements
2.0
1.6
0.03
0.7
0.6
0.01
Pension settlement
1.5
1.1
0.03
21.1
16.1
0.36
Acquisition-related amortization(3)
28.6
22.4
0.53
25.8
20.1
0.44
Discrete tax items(4)
—
(0.2
)
(0.01
)
—
(3.3
)
(0.07
)
Total adjustments
30.1
0.71
41.6
0.91
Adjusted net income
$
163.5
$
3.90
$
204.0
$
4.47
(1)
The impact to net income reflects the tax effect of noted items, which is calculated at a blended tax rate based on Carlisle's operations and the jurisdictions in which we operate.
(2)
The per share impact of adjustments to each period is based on diluted shares outstanding using the two-class method.
(3)
Acquisition-related amortization includes the amortization of customer relationships, technology, trade names and other intangible assets recorded in purchase accounting in connection with a business combination. These intangible assets contribute to revenue generation and the amortization of these assets will recur until such intangible assets are fully amortized.
(4)
Discrete tax items include current period tax expense or benefit related to prior year items, excess tax benefits from stock compensation, the tax impact of foreign currency gains and losses, or changes in tax laws or rates.
Carlisle Companies Incorporated
Unaudited Non-GAAP Financial Measures - Adjusted Net Income and Adjusted EPS
Year Ended
December 31, 2025
Year Ended
December 31, 2024
(in millions, except per share amounts)
Pre-tax
Impact
After-tax
Impact(1)
Impact to Diluted EPS(2)
Pre-tax
Impact
After-tax
Impact(1)
Impact to Diluted EPS(2)
Net income (GAAP)
$
740.7
$
17.12
$
1,311.8
$
27.82
Less: Income from discontinued operations (GAAP)
(1.8
)
(0.04
)
446.7
9.48
Income from continuing operations (GAAP)
742.5
17.16
865.1
18.34
Plus (gains) / losses and costs from:
Acquisitions
11.5
8.8
0.20
15.0
11.4
0.24
Dispositions
(0.4
)
(0.2
)
—
(0.4
)
(0.3
)
—
Restructuring
9.8
7.6
0.17
2.9
2.3
0.05
Casualty losses and insurance recoveries
—
—
—
(5.0
)
(3.8
)
(0.08
)
Legal settlements
3.6
2.8
0.06
2.6
2.0
0.04
Pension settlement
3.0
2.3
0.06
21.1
16.1
0.34
Acquisition-related amortization(3)
114.2
87.9
2.03
96.3
73.2
1.55
Discrete tax items(4)
—
(12.3
)
(0.28
)
—
(13.1
)
(0.28
)
Total adjustments
96.9
2.24
87.8
1.86
Adjusted net income
$
839.4
$
19.40
$
952.9
$
20.20
(1)
The impact to net income reflects the tax effect of noted items, which is calculated at a blended tax rate based on Carlisle's operations and the jurisdictions in which we operate.
(2)
The per share impact of adjustments to each period is based on diluted shares outstanding using the two-class method.
(3)
Acquisition-related amortization includes the amortization of customer relationships, technology, trade names and other intangible assets recorded in purchase accounting in connection with a business combination. These intangible assets contribute to revenue generation and the amortization of these assets will recur until such intangible assets are fully amortized.
(4)
Discrete tax items include current period tax expense or benefit related to prior year items, the tax impact of foreign currency gains and losses, or changes in tax laws or rates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260203479526/en/
Mehul Patel
Vice President, Investor Relations
(310) 592-9668
mpatel@carlisle.com
Original: Carlisle Companies Reports Fourth Quarter Results
TheFinalCD
13 years ago
Kcentra®, from CSL Behring, Receives FDA Approval for Use in Warfarin Reversal in Patients Undergoing Surgery
Print
Alert
CSL Ltd (ASX:CSL)
Intraday Stock Chart
Today : Friday 13 December 2013
Click Here for more CSL Ltd Charts.
KING OF PRUSSIA, Pa., Dec. 13, 2013 /PRNewswire/ -- CSL Behring today announced that Kcentra® (Prothrombin Complex Concentrate [Human]) has received U.S. Food and Drug Administration (FDA) approval for an expanded indication -- urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients needing an urgent surgery or other invasive procedure. Kcentra, approved by the FDA in April 2013 for the urgent reversal of warfarin therapy in adult patients with acute major bleeding, is the only non-activated 4-factor prothrombin complex concentrate (4F-PCC) indicated in the U.S. for these uses.
(Logo: http://photos.prnewswire.com/prnh/20130627/NY39350LOGO)
"When patients who are taking warfarin require an urgent surgical or invasive procedure, it is critical to quickly restore their coagulation status," said Joshua N. Goldstein, M.D., Ph.D., Department of Emergency Medicine, Massachusetts General Hospital. "Kcentra is an important new option for such cases; it does not require blood-type matching or thawing, and restores clotting factors more quickly than plasma. We anticipate that emergency physicians, surgeons and other hospital clinicians will welcome the expanded indication."
Kcentra helps restore blood coagulation by replenishing the levels of clotting factors that were depleted by warfarin therapy. Kcentra contains four vitamin K-dependent factors: Factor II (prothrombin), Factor VII, Factor IX and Factor X, as well as antithrombotic Proteins C and S.
Warfarin is used each year by approximately three to four million people in the U.S. to prevent blood clots from forming following a stroke, heart attack, heart valve surgery, deep vein thrombosis/pulmonary embolism, or certain types of irregular heartbeat, such as atrial fibrillation.[1],[2] Due to the deficiency in blood clotting factors induced by warfarin treatment, patients are at increased risk of bleeding, especially if undergoing an urgent surgery or invasive procedure.
"At CSL Behring, we are committed to improving the lives of people with serious health conditions by continuously working to address unmet medical needs with novel therapies," said Lynne Powell, Senior Vice President, North America Commercial Operations, CSL Behring. "The expanded indication for Kcentra in patients on warfarin therapy needing an urgent surgery or invasive procedure is another example of this commitment."
About the Urgent Surgery/Invasive Procedure Clinical Trial
The prospective, randomized, Phase IIIb study used as the basis for the FDA approval of the expanded indication for Kcentra included 168 evaluable patients on Vitamin K antagonist therapy, e.g., warfarin, who required urgent replacement of their Vitamin K-dependent clotting factors due to the need for an urgent surgery/invasive procedure. Kcentra was superior to plasma in achieving the endpoints of hemostatic efficacy for the time period from the start of infusion of Kcentra or plasma until the end of the urgent surgery or other invasive procedure (89.7 percent of patients treated with Kcentra versus 75.3 percent treated with plasma) and INR reduction (to less than or equal to 1.3) at 30 minutes after the end of infusion (55.2 percent of patients treated with Kcentra versus 9.9 percent of patients treated with plasma).
The secondary endpoints included plasma levels of major clotting factors (Factors II, VII, IX, X, antithrombotic proteins C and S) and safety and tolerability (including all-cause mortality). A single Kcentra infusion produced a rapid and sustained increase in plasma levels of clotting Factors II, VII, IX, and X within 30 minutes after the end of infusion with 89 percent less volume (90 mL +/-32 mL versus 819 mL +/- 231 mL) than plasma. Additionally, infusion time with Kcentra was nearly seven times faster than with plasma (21 minutes versus 141 minutes for plasma).
Kcentra had a safety profile comparable to plasma. The most common adverse reactions (frequency greater than or equal to 2.8%) observed in patients receiving Kcentra in both the Acute Major Bleeding Study and the Urgent Surgery/Invasive Procedure study were headache, nausea/vomiting, hypotension and anemia. The most serious adverse reactions were thromboembolic events including stroke, pulmonary embolism and deep vein thrombosis.
About Kcentra®
In more than 25 countries, CSL Behring markets Kcentra as Beriplex® or Confidex®.
In December 2012, the FDA granted Orphan Drug Designation for Kcentra for the treatment of patients needing urgent reversal of Vitamin K antagonist therapy due to major bleeding and/or surgical procedures. The FDA's Orphan Drug Designation program provides orphan status to unique drugs and biologics defined as those intended for the safe and effective treatment or prevention of rare diseases that affect fewer than 200,000 people in the U.S. Orphan designation qualifies the sponsor of the product for important tax credits, elimination of FDA license application fees and certain marketing incentives.
Important Safety Information
Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA -- e.g., warfarin) therapy in adult patients with acute major bleeding or the need for urgent surgery or other invasive procedure. Kcentra is for intravenous use only.
WARNING: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS
Patients being treated with Vitamin K antagonist therapy have underlying disease states that predispose them to thromboembolic events. Potential benefits of reversing VKA should be weighed against the risk of thromboembolic events, especially in patients with history of such events. Resumption of anticoagulation therapy should be carefully considered once the risk of thromboembolic events outweighs the risk of acute bleeding. Both fatal and nonfatal arterial and venous thromboembolic complications have been reported in clinical trials and postmarketing surveillance. Monitor patients receiving Kcentra, and inform them of signs and symptoms of thromboembolic events. Kcentra was not studied in subjects who had a thromboembolic event, myocardial infarction, disseminated intravascular coagulation, cerebral vascular accident, transient ischemic attack, unstable angina pectoris, or severe peripheral vascular disease within the prior 3 months. Kcentra might not be suitable for patients with thromboembolic events in the prior 3 months.
Kcentra is contraindicated in patients with known anaphylactic or severe systemic reactions to Kcentra or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and human albumin). Kcentra is also contraindicated in patients with disseminated intravascular coagulation. Because Kcentra contains heparin, it is contraindicated in patients with heparin-induced thrombocytopenia (HIT).
Hypersensitivity reactions to Kcentra may occur. If patient experiences severe allergic or anaphylactic type reactions, discontinue administration and institute appropriate treatment.
In clinical trials, the most frequent (greater than or equal to 2.8%) adverse reactions observed in subjects receiving Kcentra were headache, nausea/vomiting, hypotension, and anemia. The most serious adverse reactions were thromboembolic events, including stroke, pulmonary embolism and deep vein thrombosis.
Kcentra is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
The safety and efficacy of Kcentra in pediatric use have not been studied, and Kcentra should be used in women who are pregnant or nursing only if clearly needed.
For more information about Kcentra, please visit www.kcentra.com or call toll-free 1-855-4KCENTRA. For full prescribing information, please visit www.kcentra.com/prescribing-information.aspx.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.
Media Contacts:
Greg Healy
Senior Manager, Public Relations & Communications
CSL Behring
1-610-878-4841
greg.healy@cslbehring.com
Etanjalie Ayala
Weber Shandwick
1-212-445-8225
eayala@webershandwick.com
[1] Zareh M, Davis A, Henderson S. Reversal of warfarin-induced hemorrhage in the emergency department. West J Emerg Med. 2011;12(4):386-392.
[2] Raife TJ, Rose JS, Lentz SR. Bleeding from acquired coagulation defects and antithrombotic therapy. In: Simon TL, Snyder EL, Stowell CP, Strauss RG, Solheim BG, Petrides M, eds. Rossi's Principles of Transfusion Medicine. 4th ed. Hoboken, NJ: Wiley Blackwell; 2009; chapter 24.
SOURCE CSL Behring
Copyright 2013 PR Newswire
Penny Roger$
14 years ago
~ $CSL ~Multi chart fix and On the house shots of DD!! Version 3.2.3
~ Barchart: http://barchart.com/quotes/stocks/CSL?
~ OTC Markets: http://www.otcmarkets.com/stock/CSL/company-info
~ Google Finance: http://www.google.com/finance?q=CSL
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=CSL#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=CSL+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=CSL
Finviz: http://finviz.com/quote.ashx?t=CSL
~ BusyStock: http://busystock.com/i.php?s=CSL&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=CSL&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=CSL
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=CSL
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=CSL
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=23448&srchyr=2011&SearchStr=CSL
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=CSL
~ MarketWatch: http://www.marketwatch.com/investing/stock/CSL/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=CSL
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CSL
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CSL&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CSL&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CSL&size=l&frequency=60&color=g
DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=CSL
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=CSL
Check those searches for recent CSL mentions. If CSL is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a cCSLnt list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=8&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=2&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=25&y=5
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=8&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=2&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=36&y=14
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=8&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=2&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=28&y=15
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=6&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=39&y=17
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=6&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=35&y=12
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=6&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=23&y=19
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=18&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=8&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=38&y=6
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=18&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=8&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=30&y=11
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=&symb=CSL&time=18&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=8&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=35&y=14
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=3&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=7&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=39&y=14
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=3&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=7&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=20&y=16
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=3&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=7&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=46&y=6
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=1&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=6&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=42&y=20
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=1&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=6&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=36&y=11
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=1&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=6&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=46&y=11
Volume, MACD, ADX 3 EMA Par sar - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=1&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=9&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=16&lf=1&lf2=4&lf3=1024&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=31&y=14
RSI, Money Flow, Volume Accumulation, 3sma, Bollinger bands - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=1&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=9&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=2&lf2=512&lf3=4096&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=23&y=15
Price Channel, Momentum, Volatility Slow, P/E Ratio - http://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=True&insttype=Stock&symb=CSL&time=1&startdate=1%2F4%2F1999&enddate=11%2F21%2F2011&freq=9&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=6&maval=9&uf=128&lf=65536&lf2=16384&lf3=16777216&type=4&style=380&size=2&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11&x=22&y=15
---------------------
---------------------
* If a symbol changes or adds a D, etc. Message me for an updated version.
Twitter: @MACDgyver ---> CSL <---
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Monksdream
2 years ago
baglady
14 years ago
Register with Email
Hot Features
Premium
